Summary: The blood-brain barrier (BBB) stands as one of the human body’s most formidable protective interfaces, strictly shielding the central nervous system from circulating toxins. However, this same evolutionary defensive shield blocks over 98% of small-molecule drugs and nearly all large-molecule biopharmaceuticals from reaching therapeutic targets in the brain. This impenetrable barrier remains the primary bottleneck in treating devastating neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and malignant glioblastoma.
While nanomedicines (nanocarriers engineered to slip past the BBB) offer a promising path forward, their real-world performance has historically been unpredictable. The moment an engineered nanoparticle enters the bloodstream, it is instantly blanketed by a dense, chaotic layer of host blood proteins known as a protein corona. Traditionally viewed by biophysicists as a catastrophic design failure that cloaks target ligands and redirects drugs to the liver for destruction, a new Perspective fundamentally flips the script.
An international research team argues that the protein corona should not be treated as an unwanted obstruction, but rather as a highly dynamic, programmable navigation interface that can be engineered to systematically guide nanomedicines through the cellular corridors of the blood-brain barrier.
Key Facts
- The Transcytosis Paradigm Shift: The perspective steers neuro-oncology and pharmacology away from relying on “passive leakage” through damaged vessels, prioritizing receptor-mediated transcytosis (RMT), a cellular pathway that couples front-end surface recognition with directional transport through the endothelial cell.
- The Five-Stage Corona Matrix: The authors map the lifespan of a brain-targeted nanomedicine into five connected, stage-aware checkpoints: circulatory screening, endothelial receptor binding, internalization, intracellular trafficking/sorting, and polarized exocytosis (release on the brain side).
- The Apolipoprotein Trojan Horse: By tuning a nanoparticle’s surface charge and lipid chemistry, it can be engineered to specifically catch dysopsonins (like apolipoproteins or transferrin) out of the patient’s own blood. This self-assembled corona then acts as a natural biological bridge, tricking endothelial receptors like LRP1 or TfR into swallowing the drug.
- Intracellular Endocytic Remodeling: Once inside the cell, the corona doesn’t remain static; blood-derived proteins are gradually stripped and swapped with intracellular endosomal proteins. This internal remodeling determines whether the drug is recycled backward into the blood, dumped into lysosomes for degradation, or safely ferried to the brain side.
- The Translational Bottleneck: The authors caution that rodent models routinely overestimate delivery potential due to differences in vascular density, and highlight that glioblastoma tumors feature highly unpredictable patches of fully intact BBB and leaky blood-tumor barriers (BTB).
- Precision Patient Fingerprinting: The future of nanoneuroscience lies in matching particle structures to a patient’s individual plasma protein fingerprint and unique disease state, using machine learning, top-down proteomics, and blood-brain-barrier-on-a-chip testing platforms to write custom delivery software into the corona itself.
Source: Science China Press
The blood-brain barrier is one of the body’s most effective protective interfaces. It helps keep harmful substances away from the brain, but it also blocks many medicines from reaching brain tissue. This barrier remains a major challenge for treating neurological diseases, including Alzheimer’s disease, Parkinson’s disease and malignant glioma.
Nanomedicines offer one possible route forward because they can be designed to interact with natural transport pathways at the barrier. Yet their performance in the body is often difficult to predict.
A nanocarrier that looks precisely engineered in the laboratory may look very different once it enters the bloodstream. Proteins rapidly attach to its surface and form a protein corona. This layer can hide engineered targeting ligands, introduce new biological signals or redirect the carrier toward clearance organs.
In a new Perspective published in Science Bulletin, Changjian Xie, Iseult Lynch, Chunying Chen and Zhiling Guo argue that the protein corona should not be treated only as an unwanted coating. Instead, they propose that it can act as a dynamic navigation interface that shapes how nanomedicines are recognized, internalized, sorted and released across the blood-brain barrier.
The article moves the discussion beyond passive leakage. In many brain diseases, passive movement through a disrupted barrier is limited, heterogeneous or unreliable. Receptor-mediated transcytosis provides a more physiologically relevant route because it couples recognition at the endothelial surface with directional transport through the cell. The authors emphasize that successful delivery depends not only on uptake, but also on the intracellular pathway that follows uptake.
The Perspective organizes protein corona behavior into five connected stages. These are circulatory screening, receptor binding, internalization, intracellular trafficking and release on the brain side. During circulation, coronas rich in immune proteins may promote rapid clearance, while coronas enriched in selected dysopsonins or receptor-facing proteins may extend circulation and improve the chance of blood-brain barrier engagement. At the endothelial surface, corona components such as apolipoproteins or transferrin may help connect nanocarriers with receptors including LRP1 and transferrin receptor.
After internalization, the corona continues to change. Blood-derived proteins can be replaced or supplemented by proteins from endocytic and cellular compartments. This remodeling may determine whether a carrier is recycled back to the blood, sent to lysosomes for degradation or transported toward release on the brain side. The authors therefore highlight intracellular sorting and polarized exocytosis as central design challenges for brain-targeted nanomedicine.
The article also reviews strategies for manipulating the corona. These include tuning particle size, surface chemistry and lipid composition to bias the corona that forms in vivo. Another approach is recruitable corona engineering, in which nanocarriers are designed to capture functional endogenous proteins in blood and use them as biological bridges to endothelial receptors. Biomimetic pre-coating and shielding strategies may also help extend circulation while preserving access to the receptors needed for transport.
Several translational bottlenecks remain. Only a small fraction of injected nanomedicine typically reaches diseased tissue, and brain delivery faces additional constraints from the blood-brain barrier, blood-tumor barrier and active efflux systems. Rodent models may overestimate delivery potential. Stimulus-responsive carriers may release their payload too early in off-target tissues. Long-term safety, anti-PEG immune responses and scalable quality control also require closer attention.
Glioblastoma presents a particularly difficult case. The disease contains regions with an intact blood-brain barrier and regions with a more permeable blood-tumor barrier. This creates uneven nanomedicine exposure within and between lesions. The authors suggest that future development will need more informative models and trial designs that combine molecular profiling with biodistribution, pharmacokinetic and imaging readouts.
Looking ahead, the authors call for precision corona design. Future nanocarriers may need to be matched to patient-specific plasma protein fingerprints and disease states. Near-native corona capture, top-down proteomics, molecular dynamics simulation, artificial intelligence-assisted prediction, brain organoids and blood-brain-barrier-on-chip systems could together turn the protein corona into a measurable and programmable quality attribute for brain delivery.
By reframing the protein corona as a stage-aware and potentially programmable interface, the Perspective provides a roadmap for making blood-brain barrier transcytosis more predictable, controllable and clinically relevant.
Key Questions Answered:
A: In a laboratory setting, scientists can engineer a nanoparticle with perfect, pristine target keys (ligands) designed to click directly into the brain’s cellular doorways. However, a living bloodstream is a chaotic soup of sticky biological proteins. Within fractions of a millisecond after injection, hundreds of host blood proteins smash into the nanoparticle, completely burying the beautifully engineered surface under a thick, accidental shell called a protein corona. The brain’s receptors no longer see the cure you designed; they just see a generic clump of blood proteins, which the body’s immune cells rapidly grab and flush down the liver or spleen.
A: Instead of fighting the protein corona, the authors propose a strategy called “recruitable corona engineering.” Scientists can deliberately craft a nanoparticle’s surface chemistry, electrical charge, and fat composition so that it acts like a specific magnetic trap. When it dives into the bloodstream, it is engineered to selectively pull out highly beneficial proteins already floating in the patient’s blood, such as apolipoproteins or transferrin. The nanoparticle essentially uses the host’s own blood to weave its own camouflage jacket. This self-assembled coating is the perfect shape to lock directly into the blood-brain barrier’s native nutrient transport systems, letting the cell swallow it whole.
A: Getting inside the cell is only half the battle. Once an endothelial cell at the blood-brain barrier swallows a drug carrier, it places it inside a moving vesicle (an endosome) and decides what to do with it. This is a strict internal sorting station. The cell’s natural instinct is to either spit the foreign object back out into the blood where it came from, or route it to a lysosome, the cell’s recycling furnace, to burn it up. The protein corona continues to evolve inside the cell, swapping its blood outer shell for internal cellular proteins. Nanomedicines must be engineered to survive this internal swap and purposefully trigger “polarized exocytosis”, the specific command that tells the cell to steer the vesicle across the entire cell body and eject the drug safely out onto the brain side.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurotech research news
Author: Siyun Qin
Source: Science China Press
Contact: Siyun Qin – Science China Press
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Navigating the transcytosis highway: engineering protein coronas for enhanced drug delivery across the blood–brain barrier” by Changjian Xie, Iseult Lynch, Chunying Chen, Zhiling Guo. Science Bulletin
DOI:10.1016/j.scib.2026.05.040
Abstract
Navigating the transcytosis highway: engineering protein coronas for enhanced drug delivery across the blood–brain barrier
The blood–brain barrier (BBB) serves as a critical and highly selective interface between the peripheral vasculature and the brain parenchyma. Its protective function also makes it a major obstacle to brain drug delivery, which continues to limit the treatment of neurological diseases such as Alzheimer’s disease, Parkinson’s disease and malignant glioma.
Most non-invasive approaches that aim to bypass the BBB still suffer from major limitations, including poor targeting precision, rapid clearance, off-site toxicity, and inconsistent delivery efficiency. Among these approaches, nanomedicine is particularly attractive because it can, in principle, engage endogenous transport pathways without disrupting barrier integrity.
